Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Diabetes mellitus is a chronic metabolic disorder affecting millions globally, characterized by hyperglycemia and leading to severe complications.
• Current first-line anti-diabetic drugs like sulfonylureas and thiazolidinediones have limitations including low bioavailability and frequent dosing requirements.
• Existing treatments often necessitate multiple medications, increasing complexity and potential side effects for patients.

Purpose of the Study:

• To review recent advancements in nano-based drug delivery systems for improved diabetes management.
• To discuss the safety and toxicity profiles of anti-diabetic drugs delivered via nanocarriers.
• To explore future perspectives for nanomedicine in the treatment of diabetes.

Main Methods:

• Literature search conducted on electronic databases, focusing on English publications from 2014 to 2024.
• Analysis of various nanocarrier systems including polymeric nanoparticles, nanoliposomes, nanocrystals, nanosuspensions, and inorganic nanoparticles.
• Evaluation of how nanotechnology enhances drug stability, bioavailability, and therapeutic efficacy.

Main Results:

• Nanotechnology has enabled the development of diverse nanocarriers that improve anti-diabetic drug stability and bioavailability.
• These nanocarrier systems facilitate more effective delivery of anti-diabetic drugs and natural compounds.
• Nanomedicine shows potential for minimizing side effects and enhancing patient compliance in diabetes treatment.

Conclusions:

• Nano-based drug delivery systems represent a significant advancement in managing diabetes mellitus.
• These systems enhance therapeutic efficacy and patient compliance, offering a more effective treatment approach.
• The clinical implementation of nanodrugs could revolutionize diabetes care and improve patient quality of life.